Login to Your Account



Isarna gets $18M for antisense turnaround

By Cormac Sheridan
Staff Writer

Tuesday, January 7, 2014
Isarna Therapeutics GmbH raised 13 million (US$17.7 million) in new investments and has secured access to a new chemistry platform to take a fresh stab a developing antisense inhibitors of transforming growth factor-beta (TGF-beta) in oncology indications.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription